Washington, DC – October 17, 2016 – Cooley advised Prasco Laboratories on its agreements with Teva Pharmaceutical Industries and Shire to acquire the rights to distribute authorized generic versions of Adderall XR® Extended Release Capsules, and represented Prasco before the Federal Trade Commission in obtaining approval for the acquisition.
The FTC required Teva to divest its authorized generic versions of Adderall XR – available in 5 mg, 10 mg, 15 mg, 20 mg and 30 mg capsules – as a precondition to acquiring Allergan plc’s generics business.
Prasco is a privately held healthcare company with more authorized generic partnerships than any other company.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.